Follistatin-344
Also known as: FS-344, FS344, Follistatin 344, FST344, Follistatin (344 aa isoform)
Endogenous glycoprotein / activin-binding protein; myostatin inhibitor
What it is
Follistatin-344 is a peptide people use for muscle building, primarily because it inhibits myostatin — the body's natural brake on muscle growth. It's studied for muscle wasting diseases and has been used off-label by athletes seeking physique enhancement. No FDA-approved use; prohibited by WADA; most evidence from animal models.
The scientific side
Follistatin-344 (FS-344) is a 344-amino-acid isoform of follistatin, a single-chain gonadal glycoprotein produced by alternative splicing of the follistatin gene (PMID 3153465, PMID 3380788, PMID 3365249). It acts as a specific activin-binding protein, neutralizing activin and thereby inhibiting pituitary follicle-stimulating hormone (FSH) release (PMID 3153465, PMID 3380788). Because myostatin (GDF-8) is a TGF-β superfamily member related to activin, follistatin also inhibits myostatin signaling; overexpression of follistatin in skeletal muscle suppresses Smad2 phosphorylation (a downstream myostatin signal) and activates Akt phosphorylation, resulting in myofiber hypertrophy and increased skeletal muscle mass. Follistatin also inhibits bone morphogenetic proteins (BMPs). The 344-amino-acid precursor form contains a heparin-binding domain that causes rapid tissue sequestration, resulting in a short systemic half-life after parenteral administration compared to engineered variants. Follistatin is expressed broadly across gonadal and extragonadal tissues including muscle, kidney, brain, pituitary, and vascular endothelium (PMID 1979488, PMID 8895365).
Class: Endogenous glycoprotein / activin-binding protein; myostatin inhibitor
Administration & storage
- Administration
- Subcutaneous injection into the abdomen (PMID: 32671599)
- Storage
- No storage conditions for FS344 are described in the reviewed abstracts.
- Cautions
- Black market FS344 products are frequently mislabeled or adulterated: only 9 of 17 tested products actually contained follistatin; others contained unrelated growth-promoting peptides such as MGF and GHRP-2.,All nine black market FS344 products that contained follistatin were His-tagged and contained a high degree of oligomers, raising concerns about product purity and immunogenicity.,High-dose subcutaneous FS344 injection was associated with central serous chorioretinopathy (CSCR) in 11 bodybuilding athletes; recurrent CSCR occurred in three patients with multiple injection histories.,Rigorous human safety data for FS344 are scarce and there is potential for serious harm; the compound is sold on the black market without regulatory oversight.,Sterile technique is essential when handling any injectable compound; no specific sterility data for FS344 formulations are available from the reviewed literature.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. No approved pharmaceutical formulations of follistatin noted in reviewed literature.
Prohibited — listed under Chapter S4 of the WADA 2019 List of Prohibited Substances and Methods.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Skeletal muscle mass enhancement / myostatin inhibition Animal studies only
- Transgenic Duroc pigs overexpressing human FST specifically in muscle exhibited significantly higher lean meat percentage (72.95 ± 1.0% vs. 69.18 ± 0.97% in wild-type), myofiber hypertrophy, reduced Smad2 phosphorylation, and increased Akt phosphorylation in skeletal muscle. No cardiac muscle hypertrophy or reproductiv PMID 27787698 Chang et al., Transgenic Research (2017)
- Native FST315 showed poor PK/PD properties for systemic use. An engineered Fc-fusion variant with reduced heparin-binding showed ~100-fold improvement in terminal half-life and ~1600-fold improvement in exposure, and produced robust, dose-dependent muscle effects in mouse models of muscle atrophy and degeneration. Nati PMID 23249626 Datta-Mannan et al., J Pharmacol Exp Ther (2013)
- Sports/athletic performance enhancement (unapproved, 'gray market' use) Animal studies only
- FS-344 is marketed directly to patients as a performance- and image-enhancing peptide to increase muscle mass. Many unapproved peptides including FS-344 demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce and there is potential for serious harm to patie PMID 41966639 Mendias & Awan, Sports Medicine (2026)
- Biomarker of physical functional impairment in rheumatoid arthritis Human observational
- In a cross-sectional study of 57 female RA patients and 20 controls, serum follistatin levels were significantly elevated in RA vs. controls (175 ± 119 vs. 133 ± 47; p=0.030). Higher follistatin correlated with deteriorated physical function (r=0.491; p<0.001) and severe disease activity (r=0.344; p=0.009). RA patients PMID 40943156 Gonzalez-Ponce et al., Int J Mol Sci (2025)
- FSH suppression / reproductive endocrinology (endogenous role) Mixed
- Original structural characterization of follistatin as a novel FSH-release inhibiting polypeptide from the gonad. Two isoforms (344 aa and 317 aa precursors) were identified by cDNA cloning. PMID 3153465 Esch et al., Mol Endocrinol (1987)
- hCG induced follistatin mRNA levels up to ~9-fold above basal in human granulosa-luteal cells in vitro, with maximal response at 6–8 h. Both 344 aa and 317 aa transcript variants were detected. PMID 7956942 Tuuri et al., Endocrinology (1994)
- Glaucoma / trabecular meshwork pathophysiology (endogenous expression studies) In vitro only
- FST mRNA and protein (including FST 317/344 isoforms) were significantly elevated in glaucomatous vs. normal human trabecular meshwork cells. TGF-β2 significantly induced FST expression, suggesting a possible role for follistatin in glaucoma pathogenesis via BMP inhibition. PMID 23010638 Fitzgerald et al., Invest Ophthalmol Vis Sci (2012)
- Anti-doping detection (prohibited substance identification) In vitro only
- A detection method using immunomagnetic purification followed by SDS-PAGE and Western blotting was developed for black market FS344 in serum and urine. Detection limit: ~0.1 ng/mL in urine (10 mL); ~5 ng/mL in serum (100 µL). All nine of 17 products tested that actually contained follistatin were His-tagged FS344 with PMID 31758732 Reichel et al., Drug Test Anal (2019)
Safety signals
- Central serous chorioretinopathy (CSCR): 11 male bodybuilding athletes developed CSCR after high-dose subcutaneous FS344 injections; 10 had unilateral and 1 had bilateral findings. In 8 patients with a single injection, subretinal fluid resolved within a mean of 2.3 ± 0.7 months. Recurrent CSCR developed in 3 patients with multiple injection histories. PMID 32671599
- Black market products labeled as FS344 frequently contain adulterants (e.g., MGF, GHRP-2) rather than follistatin, posing unpredictable safety risks to users. PMID 31758732
- Potential for serious harm to patients cited in sports medicine review; rigorous human safety data are described as scarce for FS344 and similar unapproved peptides. PMID 41966639
Contraindications
- No formal contraindications are stated in the reviewed literature. History of or susceptibility to central serous chorioretinopathy should be considered a potential risk factor given the reported association. PMID 32671599
Protocol
100 mcg intramuscular (im) injection, once daily. Cycle: 10 days.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Subcutaneous injection (abdomen) | 1 mg per injection (complete 1 mg vials administered subcutaneously) | Single injection (8 patients) or multiple injections (3 patients) | human | Research PMID 32671599 |
| intramuscular (IM) injection | 100 mcg | once daily · 10 days | bodybuilders and advanced biohackers seeking muscle hypertrophy | [Community] |
| intramuscular (IM) injection | 200 mcg | once daily · 10 days | experienced bodybuilders seeking aggressive muscle hypertrophy | [Community] |
| intramuscular (IM) injection — site-specific | 100 mcg | once daily · 10 days | bodybuilders targeting localized muscle group hypertrophy | [Community] |
| intramuscular (IM) injection | 100 mcg | once daily · 10–30 days | biohackers and anti-aging enthusiasts | [Community] |
| intramuscular (IM) injection | 50 mcg | once daily · 10 days | first-time users or cautious biohackers starting with a conservative dose | [Community] |
All studies (14)
- PMID 40943156 Human observational
Biomarker of physical functional impairment in rheumatoid arthritis - PMID 3153465 Mixed
FSH suppression / reproductive endocrinology (endogenous role) - PMID 7956942 Mixed
FSH suppression / reproductive endocrinology (endogenous role) - PMID 1979488
- PMID 3365249
- PMID 3380788
- PMID 7893350
- PMID 8895365
- PMID 23010638 In vitro only
Glaucoma / trabecular meshwork pathophysiology (endogenous expression studies) - PMID 23249626 Animal studies only
Skeletal muscle mass enhancement / myostatin inhibition - PMID 27787698 Animal studies only
Skeletal muscle mass enhancement / myostatin inhibition - PMID 31758732 In vitro only
Anti-doping detection (prohibited substance identification) - PMID 32671599
1 mg per injection (complete 1 mg vials administered subcutaneously) Subcutaneous injection (abdomen) (human) - PMID 41966639 Animal studies only
Sports/athletic performance enhancement (unapproved, 'gray market' use)
Frequently asked
What does follistatin-344 do, and how does it work?
Follistatin-344 is a 344-amino-acid isoform of follistatin, a naturally occurring glycoprotein that binds and neutralizes activin and myostatin, both members of the TGF-β superfamily. By inhibiting myostatin signaling, follistatin can promote skeletal muscle growth. In transgenic pigs overexpressing follistatin specifically in muscle, researchers observed reduced Smad2 phosphorylation (a myostatin signaling marker), increased Akt phosphorylation, myofiber hypertrophy, and higher lean meat percentage compared to wild-type animals. It also inhibits FSH release from the pituitary.
Is follistatin-344 legal to use or buy?
Follistatin is explicitly prohibited under Chapter S4 of the WADA 2019 List of Prohibited Substances and Methods. No approved pharmaceutical formulations of follistatin are noted in the reviewed literature. It is sold on the black market largely outside of regulatory oversight. Regulatory status in specific jurisdictions (e.g., FDA, Health Canada) requires manual verification with those agencies.
What dose of follistatin-344 should I use for muscle building?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the only human dosing data in the reviewed literature comes from a case series of bodybuilding athletes who each injected complete 1 mg vials subcutaneously into the abdomen — an exposure that was associated with central serous chorioretinopathy (a potentially serious eye condition) in all 11 reported patients. There are no controlled human clinical trials establishing a safe or effective dose.
Is follistatin-344 safe? What are the risks?
The reviewed literature identifies several safety concerns: (1) High-dose subcutaneous FS344 injections were associated with central serous chorioretinopathy (CSCR) in 11 bodybuilding athletes, including recurrent cases in those who injected multiple times. (2) Black market products labeled as FS344 frequently contain adulterants — only 9 of 17 tested products actually contained follistatin; others contained MGF and GHRP-2. (3) All confirmed follistatin-containing products were His-tagged with a high degree of oligomers, raising purity concerns. (4) A sports medicine review characterizes rigorous human safety data as scarce and notes potential for serious harm.
Can follistatin-344 cause eye problems?
Yes — the reviewed literature includes a retrospective case series of 11 male bodybuilding athletes who developed central serous chorioretinopathy (CSCR) — a condition involving fluid accumulation under the retina causing decreased visual acuity — following high-dose subcutaneous follistatin-344 injections. In 8 patients with a single injection, subretinal fluid resolved within an average of 2.3 ± 0.7 months. Recurrent CSCR developed in 3 patients who had multiple injections. The authors concluded that follistatin-344 injection can be considered a risk factor for CSCR.
How is follistatin-344 different from follistatin-315 or follistatin-288?
Follistatin isoforms arise from alternative splicing of the same gene. The 344-amino-acid precursor (FS344) encodes a mature protein of 315 amino acids (FS315) after signal peptide cleavage; a shorter precursor of 317 amino acids encodes a mature form of 288 amino acids (FS288) that lacks the 27-amino-acid C-terminal domain (PMID 3153465, PMID 7893350, PMID 3365249). The C-terminal domain of FS344/315 contains a heparin-binding region that causes rapid tissue sequestration and a short systemic half-life; engineered removal of this binding activity substantially improved pharmacokinetics in animal studies. Both mRNA forms are co-expressed in most tissues, but the 344-form mRNA predominates.
Can I stack follistatin-344 with other peptides like BPC-157 or GHRP?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: follistatin-344 as a standalone compound has been associated with central serous chorioretinopathy in human case reports, and black market FS344 products have been found to contain adulterants including GHRP-2. No studies in the reviewed literature address combination use.
Where can I buy follistatin-344?
I don't recommend vendors or sources. Please consult a licensed provider. Note that follistatin is prohibited by WADA, and black market products labeled as FS344 frequently contain adulterants or are mislabeled.
Has follistatin-344 been tested in human clinical trials?
No human clinical trials for follistatin-344 are described in the reviewed literature. The only human data available are from a retrospective case series of 11 bodybuilding athletes who experienced central serous chorioretinopathy after self-administering high-dose FS344, and observational data measuring endogenous follistatin levels in rheumatoid arthritis patients. A sports medicine review notes that rigorous human safety data for FS344 are scarce.
I have rheumatoid arthritis — could follistatin help or hurt me?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What observational research has found: serum follistatin levels were significantly elevated in women with RA compared to controls, and higher follistatin correlated with greater physical functional impairment and more severe disease activity. This is an association study of endogenous follistatin levels, not a therapeutic intervention study, and does not establish whether exogenous FS344 would be beneficial or harmful in RA.